Why TG Therapeutics Stock Was Soaring This Week

Core Viewpoint - TG Therapeutics reported strong Q4 and full-year 2024 results, leading to a significant increase in stock price, with a nearly 27% rise week to date following the announcement [1][2]. Financial Performance - The company generated approximately $108.2 million in revenue for Q4 2024, more than double the nearly $44 million from the same period in 2023 [3]. - TG Therapeutics achieved a GAAP net income of $23.3 million ($0.15 per share), a turnaround from a net loss of $14.4 million in the previous year [3]. - Both revenue and earnings per share exceeded analyst expectations, with consensus estimates being less than $98 million for revenue and $0.07 for earnings per share [4]. Product Performance - The strong financial results were primarily driven by robust sales of Briumvi, the company's commercialized drug for multiple sclerosis, which benefited from its launch in Europe in partnership with Neuraxpharm [4]. Future Outlook - The company provided optimistic guidance, projecting total revenue of approximately $540 million for 2024, with around $525 million expected from Briumvi sales in the U.S. [5]. - Operating expenses are anticipated to be around $300 million [5]. - Despite its current pipeline being in early stages, TG Therapeutics shows promise for future growth, particularly with Briumvi's potential in international markets [6].